Impact of Open Label Placebo Administration on Cognition and Well-being
Not Applicable
- Conditions
- Healthy volunteers
- Registration Number
- DRKS00013557
- Lead Sponsor
- niversitätsklinikum EssenKlinik für Neurologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 167
Inclusion Criteria
Age> 18 years, successfully completed registration for the first attempt of the examination of the first section of Medicine (M1) or a comparable examination of another study section or course, Volunteers, informed consent to study participation
Exclusion Criteria
Severe medical conditions (in particular, diagnosed psychiatric comorbidities, in particular harmful substance abuse (including alcohol, cannabinoids, cocaine, amphetamines) in the last 4 weeks prior to inclusion or persistence; Known allergy or intolerance to any of the ingredients of the placebo; Parallel participation in a study using investigational medicinal products.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome variable is the documented examination performance in a standardized, regional, written multiple-choice exam (end term exam (ZAK), M1 (Medicine)) and is measured as the proportion of correctly solved tasks in all completed tasks.
- Secondary Outcome Measures
Name Time Method Secondary outcome variable is well-being before the exam and while preparing for the exam compared to scores of standardized questionnaires (PSQ20 (stress), ADS-K (depression), PSQI (sleep quality), SOMS (somatization), STAI-G-X1 (anxiety).